桡通全球 全时降压｜铂睿时 Iberis® RDN 罗马落地！意大利首都核心区域首批经桡 RDN 手术圆满成功

Core Viewpoint - The article highlights a significant clinical breakthrough in hypertension intervention at the Ospedale San Pietro FBF Roma, where the Iberis® RDN system was successfully used for the first time in two cases of renal denervation (RDN) via transradial access (TRA) [3][4]. Group 1: Clinical Breakthrough - The successful application of the Iberis® RDN system marks a new phase in minimally invasive and effective hypertension treatment in Italy [4]. - The procedures were led by experienced doctors Dario Bertolone and Roberta Serdoz, with guidance from Professor Francesco Monti and Professor Francesco Rotolo [3]. Group 2: Case Details - Case 1: A 49-year-old female patient with medication adherence issues underwent RDN treatment using the Iberis® system via left TRA. The procedure involved 6 and 8 ablations on the left and right renal arteries, respectively, and 1 ablation on the left accessory renal artery [6]. - Case 2: A 73-year-old male patient with poor control on four antihypertensive medications also received treatment via left TRA. The procedure included 8 and 7 ablations on the left and right renal arteries, respectively, and 2 ablations on the right accessory renal artery [9]. Group 3: Advantages of the Iberis® System - The Iberis® system demonstrated strong radial support, stable vascular wall adherence, and excellent maneuverability during the TRA procedures, offering a new, less invasive option compared to traditional femoral access [6]. - The emphasis on the importance of ablating accessory renal arteries was highlighted, as it contributes to more comprehensive renal nerve modulation, leading to better and longer-lasting blood pressure control [9]. Group 4: Future Implications - The successful implementation of the Iberis® RDN system in these cases provides a solid foundation for the clinical promotion of individualized and minimally invasive hypertension intervention strategies [9]. - Ongoing follow-up data is anticipated to further evaluate the long-term efficacy and safety of the Iberis® system, with the company committed to advancing RDN technology both domestically and internationally [9].